COVID disrupted cancer screening across the UK and worldwide. Discover how late diagnoses, new technologies, and NHS reforms are reshaping early detection in 2026.
COVID’s Long Shadow and the Race to Rebuild Equitable Cancer Care
Four years after the first COVID-19 lockdowns, the oncology community has reached an uncomfortable clarity: the pandemic did not just pause cancer screening — it permanently altered the epidemiology of early detection.
While much remains unknown about long-term survival trends, the impact on screening and late-stage diagnoses is now stark and quantifiable. The UK, United States, and most European systems continue to absorb the aftershocks: rising emergency presentations, a heavier stage mix, and unprecedented pressure on diagnostics and radiotherapy.
The Reality in 2026: Screening Never Fully Recovered
In the United States, early national estimates showed 22 million missed or cancelled cancer screenings in 2020 alone. Subsequent analyses from the American Cancer Society and Harvard T.H. Chan School of Public Health confirmed what clinicians suspected:
the fallout persisted into 2021–2023, disproportionately affecting low-income and minority populations.
- ACS data from 32 community health centres reported an 8% sustained decline in mammography among women aged 50–74.
- The modelling suggested 47,000 fewer mammograms and ~240 missed breast cancers over two years.
- Harvard’s modelling predicted a 10–14% surge in diagnoses in 2021–22, skewing toward advanced-stage disease.
The UK experienced a parallel crisis — but with a uniquely British twist: even as screening programmes reopened, coverage never regained pre-COVID levels.
Cervical Screening (England, 2024–25)
- Coverage in women 25–49 remains stuck at ~67.5% (down from over 70% pre-COVID).
- No ICB in England reaches the national standard of 80%.
- Inequalities widened: coverage in the most deprived areas remains 10–12 percentage points lower.
Bowel Screening
The FIT test dramatically improved uptake pre-COVID, but regional inequity remains entrenched:
- 2024–25 uptake: 67.6% nationally
- Least deprived areas: 75.8%
- Most deprived areas: 55.8%
Breast Screening
The backlog from the 2020 shutdown produced a multi-year ripple. By late 2024, Round and colleagues (British Journal of Cancer, 2024) concluded that screening activity had “stabilised, but not rebounded,” with some age groups still “structurally underserved.”
The most troubling indicator is symptomatic emergency presentation, which remains elevated in 2025–26 for colorectal and lung cancer.
Cancer Research UK’s 2025 review stated it plainly:
“The pandemic pushed cancer diagnosis several years off course. The system has not fully recovered.”
Stage Migration: The Hidden Consequence
The oncology community now confronts the feared phenomenon of stage migration — the shift toward late-stage disease after delays in detection.
Across multiple datasets (UK, US, Netherlands, Denmark):
- Higher proportions of Stage III and IV breast, colorectal and lung cancers are now being recorded.
- More patients are presenting through emergency routes.
- Treatment intensity, complexity, and cost are rising accordingly.
From a health-economic standpoint, late-stage cancer care can cost 3–10 times more than earlier-stage management. For a financially strained NHS, this is not simply a clinical burden — it is a structural economic shock.
The NHS Response in 2025–26: Rebuild, Reform, Reimagine
COVID forced the UK government and NHS England to step into a role many argued was overdue: fundamentally restructure early diagnosis pathways.
1. Community Diagnostics Centres (CDCs)
Over 160 CDCs are now operational, intended to remove pressure from hospitals by providing:
- FIT testing
- Ultrasound
- CT
- MRI
- Endoscopy
- Lung health checks
Their impact is powerful but uneven. They are helping reduce local bottlenecks, but workforce shortages continue to limit throughput.
2. NHS Early Diagnosis Strategy (2026 updates)
The post-COVID strategy emphasises:
- Risk-stratified screening (age, genetics, deprivation, smoking status)
- Targeted outreach to deprived geographies
- Expansion of the 28-Day Faster Diagnosis Standard
- Pilot integration of AI triage for imaging
The stated goal remains:
Diagnose 75% of cancers at Stage I–II by 2028.
The real-world trajectory is closer to 55–58% — a warning sign.
3. NICE and New Screening Technologies
COVID accelerated interest in non-invasive and decentralised screening, including:
- AI-supported mammography
- AI dermatology (NICE HTE24)
- HPV self-sampling
- Colon capsule endoscopy
- Blood-based tests and MCED (multi-cancer early detection) assays
- AI-augmented FIT triage in primary care
By 2026, NICE has adopted an increasingly pragmatic view: new screening technologies must not only show diagnostic accuracy but prove real-world operational value — reducing waiting times, improving equity, or lowering system-level cost.
The Coming Radiotherapy Crunch
If COVID disrupted screening, it overloaded radiotherapy.
As late-stage and oligometastatic cancers rise, demand for radiotherapy (RT) is escalating worldwide.
The numbers are unforgiving:
- 50–60% of all cancer patients need radiotherapy.
- 40–60% globally lack access.
- Low- and middle-income countries hold 80% of the global cancer burden but only 32% of RT capacity (Atun et al., Lancet Oncology).
Even high-income countries are under strain:
- Workforce shortages
- Ageing linear accelerator fleets
- Rural–urban inequalities in RT access
- Increased need for complex metastasis-directed therapy
Evidence Driving the Shift Toward Metastasis-Directed RT
The SABR-COMET trial (Palma et al.) demonstrated significant overall survival improvements with stereotactic ablative radiotherapy (SABR) for oligometastatic disease.
This has reshaped practice:
- Lung, colorectal, breast, prostate
- Low-volume metastatic disease
- Curative-intent pathways for select metastases
The Netherlands Cancer Institute’s ongoing MR-guided RT (MRgRT) trials signal the next era of high-precision, adaptive therapy — particularly valuable as later-stage disease becomes more prevalent.
2026: From Patchwork Access to Equitable Cancer Care
The pandemic exposed — and worsened — longstanding access gaps:
- Rural vs. urban RT availability
- Socioeconomic barriers to screening
- Digital exclusion for tele-oncology
- Geographic variation in PET access
- Variable uptake of innovative RT technologies such as MR-Linac and brachytherapy
Cancer centres across Europe are now pursuing three strategic imperatives:
1. Remote Treatment Planning & Virtual Expansion of RT Capacity
Cloud-based contouring, remote planning and virtual peer review allow expertise to reach underserved regions — reducing the cost of staffing small centres and enabling international collaboration.
2. Scaling Advanced Imaging (PET, PSMA PET, molecular imaging)
The shift toward oligometastatic management and targeted radionuclide therapy makes PET capacity essential, yet unevenly distributed.
3. Investing in MR-Linac, MRgRT & Modern Brachytherapy
These technologies enable:
- Real-time adaptive therapy
- Hypofractionation (reducing burden on patients and capacity)
- Treatment of tumours previously unsuitable for conventional RT
Hospitals with modern brachytherapy infrastructure can deliver treatment in hours instead of weeks, relieving surgical backlogs and reducing inpatient admissions.
Multimodal Cancer Care in the Post-COVID Era
Multimodal therapy — integrating surgery, systemic therapy and radiation — remains a cornerstone of care.
COVID disrupted the tumour board model, but it also accelerated the creation of HIPAA-compliant digital MDT platforms, now widely used for:
- Virtual tumour boards
- Cross-site collaboration
- Real-time imaging review
- Remote RT planning
- Shared decision-making with patients
These tools expanded participation, allowing rural clinicians and visiting consultants to contribute in ways not previously possible.
The Health-Economic Imperative: Prevention and Early Detection Are No Longer Optional
From a policy perspective, the lesson of COVID is brutally simple:
A health system that underinvests in early diagnosis pays exponentially more in late-stage cancer care.
The NHS’s budgetary pressure in 2026 underscores this:
- Advanced cancer care is rising in cost.
- Emergency presentations are higher.
- Radiotherapy demand is up.
- Workforce capacity remains tight.
- New therapies (immunotherapy, targeted agents, radioligands) add major financial strain.
Early detection is no longer a “public health priority.”
It is the linchpin of NHS financial sustainability.
Where Oncology Goes Next
The oncology community is entering a new phase defined not by crisis, but by reconstruction and reinvention.
Expect three defining shifts in the coming 24 months:
1. Universal adoption of risk-stratified screening models
Using deprivation, ethnicity, age, family history, and molecular risk markers to personalise screening.
2. Expansion of precision radiotherapy and metastasis-directed interventions
MR-guided adaptive therapy, SABR for oligometastatic disease, radionuclide therapy, and AI-planned RT will move from specialist centres to mainstream practice.
3. System-level redesign for equitable access
Remote treatment planning, PET expansion, modern brachytherapy, mobile screening units, community diagnostics, and digital MDTs will define the next generation of cancer care delivery.
Conclusion: The Resilience Built Now Determines the Next Decade
COVID-19 reshaped cancer care globally. It widened inequalities, delayed diagnoses, strained radiotherapy capacity, and exposed structural weaknesses in screening programmes. But it also accelerated innovation, forced operational reforms, and catalysed a once-in-a-generation rethinking of early detection.
The challenge for 2026 and beyond is not merely to “catch up,” but to build a system capable of diagnosing earlier, treating smarter, and delivering equitable care everywhere — from urban cancer hubs to rural communities and from wealthy nations to LMICs.
The capacity, technology, and resilience we build today will define cancer outcomes for the next decade.
Official / Government Data & Reports
- Department of Health & Social Care / NHS England. “NHS population screening programmes: KPI reports 2023 to 2024.” GOV.UK. Published 14 Dec 2023, last updated 20 Mar 2025.
https://www.gov.uk/government/collections/nhs-population-screening-programmes-kpi-reports-2023-to-2024 GOV.UK - Department of Health & Social Care / NHS England. “NHS population screening programmes: KPI reports 2024 to 2025.” GOV.UK. Published 13 Dec 2024.
https://www.gov.uk/government/collections/nhs-population-screening-programmes-kpi-reports-2024-to-2025 GOV.UK - NHS England. Screening statistics page: “Screening.”
https://www.england.nhs.uk/statistics/statistical-work-areas/screening/ NHS England - Scottish Public Health Observatory (ScotPHO). “Screening: data” for Scotland – includes bowel, breast, cervical, inequalities. Published 19 Nov 2024.
https://www.scotpho.org.uk/health-conditions/screening/data/ scotpho.org.uk - NHS UK. “NHS screening” – overview of screening programmes in England.
https://www.nhs.uk/tests-and-treatments/nhs-screening/ nhs.uk
Peer-Reviewed / Academic Studies
- Barclay NL et al. (2024). “The impact of the UK COVID-19 lockdown on the screening, diagnostics and incidence of breast, colorectal, lung and prostate cancer in the UK: a population-based cohort study.” Frontiers in Oncology.
https://www.frontiersin.org/articles/10.3389/fonc.2024.1370862/full Frontiers - Tan YY et al. (2024). “Impact of the COVID-19 pandemic on health-care use and outcomes for people with cancer: UK analysis.” The Lancet Regional Health.
https://www.thelancet.com/journals/landig/article/PIIS2589-7500(24)00152-3/fulltext The Lancet - Round T et al. (2024). “Transforming post pandemic cancer services.” British Journal of Cancer.
https://www.nature.com/articles/s41416-024-02596-9 Nature - Aggarwal A et al. (2023). “COVID-19 and cancer in the UK: which will prove to be the bigger challenge?” BMJ Oncology.
https://bmjoncology.bmj.com/content/2/1/e000012 bmjoncology.bmj.com - Arik A, Cairns AJG, Dodd E et al. (2023). “The effect of the COVID-19 health disruptions on breast cancer mortality for older women: A semi-Markov modelling approach.” arXiv preprint.
https://arxiv.org/abs/2303.16573 arXiv - Fetzer T, Rauh C. (2022). “Pandemic Pressures and Public Health Care: Evidence from England.” arXiv preprint.
https://arxiv.org/abs/2201.09876 arXiv
European / International Context & Data Intelligence
- European Cancer Organisation. “Impact – COVID-19 & Cancer Data Intelligence.” Time to Act campaign.
https://www.europeancancer.org/timetoact/impact/data-intelligence.html European Cancer Organisation - Maringe C et al. (2020). “The impact of the COVID-19 pandemic on cancer deaths due to delays in diagnosis in England, UK: a national, population-based modelling study.” The Lancet Oncology.
https://www.sciencedirect.com/science/article/pii/S1470204520303880 ScienceDirect
Screening Oversight / Data Definitions
- NHS England. Appendix A: “Screening standards/KPI data definitions.”
https://www.england.nhs.uk/wp-content/uploads/2025/08/screening-standards-kpi-data-appendix.docx NHS England